Results 111 to 120 of about 39,389 (304)

Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers [PDF]

open access: bronze, 2022
Yicong Bian   +10 more
openalex   +1 more source

Quantitative analysis of the binding affinity of poly(ADP-ribose) to specific binding proteins as a function of chain length

open access: yesNucleic Acids Research, 2007
Poly(ADP-ribose) (PAR) is synthesized by poly(ADP-ribose) polymerases in response to genotoxic stress and interacts non-covalently with DNA damage checkpoint and repair proteins.
J. Fahrer   +4 more
semanticscholar   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman   +7 more
wiley   +1 more source

Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition [PDF]

open access: gold, 2023
Andrea Pelliccia   +7 more
openalex   +1 more source

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol   +5 more
wiley   +1 more source

PARPs in liver diseases

open access: yesnpj Gut and Liver
Poly(ADP-ribose) polymerases (PARPs) comprise a family of 17 enzymes were initially identified for their essential roles in DNA damage repair and maintenance of genomic stability. Emerging evidence has unveiled their critical involvement in various liver
Jiaxin Xia   +3 more
doaj   +1 more source

Poly ADP-ribose polymerase-1 and health

open access: yesExperimental Biology and Medicine, 2010
Niacin (vitamin B3) is required to form nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are involved in scores of anabolic and catabolic redox reactions throughout metabolism. It is now understood that NAD+ is also a substrate for several families of ADP-ribosylation reactions, which control ...
openaire   +2 more sources

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

open access: yesMed Research, EarlyView.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy